Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study ‘TOPICS Greece’
Fecha
2021Language
en
Materia
Resumen
Background and Objectives: For chronic diseases like multiple sclerosis (MS), real-world evidence on long-term treatment outcomes is essential. The study aimed to provide long-term data on the safety and effectiveness of natalizumab in patients with relapsing-remitting MS (RRMS) treated in a routine care setting in Greece. Methods: TOPICS Greece was a multicenter, single-country, prospective 5-year observational study. Results: Between 19-Apr-2012 and 18-Dec-2014, 304 eligible adults [females: 63.2%; median age at natalizumab initiation: 38.0 years; median disease duration: 6.2 years; median Expanded Disability Status Scale (EDSS) score at baseline: 3.5] were enrolled in the study by 20 hospital-based neurologists. The 1-year annualized relapse rate (ARR) before treatment initiation was 1.859, while the ARR during the first year of treatment was 0.131, representing a significant 93% reduction (p < 0.001). The ARR over the median treatment period of 59.4 months was 0.109. Patients with ≤1 relapse in the pre-natalizumab year (46.1%) and those having received ≤1 prior disease-modifying therapy (57.9%) displayed significantly lower on-natalizumab ARR. The 1-, 2-, 3-, 4- and 5-year cumulative probabilities of EDSS progression were 3.2, 6.2, 9.7, 13.4, and 17.4%, respectively; the respective probabilities of EDSS disability improvement were 18.3, 25.1, 27.4, 28.0, and 30.1%. Over a median safety data collection period of 48.7 months, 4.6% of the patients experienced ≥ 1 serious adverse event, with infections (reported in 1.0%) being the most common. Conclusion: In real-world settings in Greece, natalizumab displayed beneficial long-term effects on disease activity and disability progression consistent with previous studies with no new serious safety signals emerging. © 2021, The Author(s).
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Replication study of GWAS risk loci in Greek multiple sclerosis patients
Hadjigeorgiou G.M., Kountra P.-M., Koutsis G., Tsimourtou V., Siokas V., Dardioti M., Rikos D., Marogianni C., Aloizou A.-M., Karadima G., Ralli S., Grigoriadis N., Bogdanos D., Panas M., Dardiotis E. (2019)Objectives: To validate in an ethnically homogeneous Greek multiple sclerosis (MS) cohort, genetic risk factors for the disease, identified through a number of previous multi-ethnic genome-wide association studies (GWAS). ... -
Brain volume dynamics in multiple sclerosis. A case-control study
Andravizou A., Artemiadis A., Bakirtzis C., Siokas V., Aloizou A.-M., Peristeri E., Kapsalaki E., Tsimourtou V., Hadjigeorgiou G.M., Dardiotis E. (2019)Objectives: In this study, we aimed to explore the extent and clinical relevance of brain volume dynamics in relapsing remitting multiple sclerosis (RRMS). Methods: Sixty-three patients with RRMS with a disease duration ... -
A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic sclerosis
Efthymiou G., Dardiotis E., Liaskos C., Marou E., Scheper T., Meyer W., Daponte A., Daoussis D., Hadjigeorgiou G., Bogdanos D.P., Sakkas L.I. (2019)Anti-human cytomegalovirus (HCMV) antibodies are considered triggers of systemic sclerosis (SSc), but such a hypothesis has been assessed in limited sub-dominant epitopes. Our aim was to systematically assess the potential ...